WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 599252
CAS#: 95510-70-6 (sodium)
Description: Omeprazole sodium is the salt analogue of Omeprazole, which binds covalently to proton pump. It inhibits gastric secretion. Used as an anttiulcerative.
MedKoo Cat#: 599252
Name: Omeprazole sodium
CAS#: 95510-70-6 (sodium)
Chemical Formula: C17H18N3NaO3S
Exact Mass:
Molecular Weight: 367.3988
Elemental Analysis: C, 55.58; H, 4.94; N, 11.44; Na, 6.26; O, 13.06; S, 8.73
Related CAS #: 95510-70-6 (sodium) 73590-58-6 (free form) 119141-88-7 (S-isomer) 95510-71-7 (potassium)
Synonym: Omeprazole sodium; H 168/68 sodium; Andra; Losec Sodium;
IUPAC/Chemical Name: sodium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
InChi Key: RYXPMWYHEBGTRV-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H18N3O3S.Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1
SMILES Code: O=S(C1=NC2=CC(OC)=CC=C2[N-]1)CC3=NC=C(C)C(OC)=C3C.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | Omeprazole sodium (H 16868 sodium) is a proton pump inhibitor (PPI). |
| In vitro activity: | The antibacterial effects of omeprazole (100, 200 and 300 mg/L) were assessed using bacterial growth curves. A dose-related permanent inhibition was seen with actively growing Gram-positive cocci. A reduced and only temporary effect was observed with Gram-negative bacilli. After 1 day the bacterial count of Helicobacter pylori in the presence of omeprazole 200 mg/L was reduced from 10(4) cfu/mL for the control to zero. Reference: J Antimicrob Chemother. 1996 Jan;37(1):145-50. https://pubmed.ncbi.nlm.nih.gov/8647756/ |
| In vivo activity: | This study revisited the effect of omeprazole treatment on the degree of anxiety-like behaviours in a cysteamine hydrochloride (HCl) induced mouse model of GI disorder using open field test (OFT), light-dark box (LDB) test and elevated plus maze (EPM). Results revealed that omeprazole treatment mitigates anxiety-related behaviours in the cysteamine HCl induced animal model of GI disorder. Thus, this study assuredly supports and validates the anxiolytic properties of omeprazole. Reference: Heliyon. 2022 Jun 24;8(6):e09787. https://pubmed.ncbi.nlm.nih.gov/35800723/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Water | 39.28 | 106.91 |
The following data is based on the product molecular weight 367.3988 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Scaringi L, Cornacchione P, Fettucciari K, Rosati E, Rossi R, Marconi P, Capodicasa E. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol. 1996 Sep;44(3):204-14. doi: 10.1046/j.1365-3083.1996.d01-300.x. PMID: 8795713. 2. Jonkers D, Stobberingh E, Stockbrügger R. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50. doi: 10.1093/jac/37.1.145. PMID: 8647756. 3. Sri Rethinavel H, Selvaraj DB, Balakrishnan SJ, Vergil Andrews JF, Joseph JHM, Kandasamy M. Omeprazole treatment manifests anxiolytic effects in a cysteamine hydrochloride induced mouse model of gastrointestinal disorder. Heliyon. 2022 Jun 24;8(6):e09787. doi: 10.1016/j.heliyon.2022.e09787. PMID: 35800723; PMCID: PMC9253648. 4. Rudra DS, Pal U, Chowdhury N, Maiti NC, Bagchi A, Swarnakar S. Omeprazole prevents stress induced gastric ulcer by direct inhibition of MMP-2/TIMP-3 interactions. Free Radic Biol Med. 2022 Mar;181:221-234. doi: 10.1016/j.freeradbiomed.2022.02.007. Epub 2022 Feb 10. PMID: 35150824. |
| In vitro protocol: | 1. Scaringi L, Cornacchione P, Fettucciari K, Rosati E, Rossi R, Marconi P, Capodicasa E. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol. 1996 Sep;44(3):204-14. doi: 10.1046/j.1365-3083.1996.d01-300.x. PMID: 8795713. 2. Jonkers D, Stobberingh E, Stockbrügger R. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50. doi: 10.1093/jac/37.1.145. PMID: 8647756. |
| In vivo protocol: | 1. Sri Rethinavel H, Selvaraj DB, Balakrishnan SJ, Vergil Andrews JF, Joseph JHM, Kandasamy M. Omeprazole treatment manifests anxiolytic effects in a cysteamine hydrochloride induced mouse model of gastrointestinal disorder. Heliyon. 2022 Jun 24;8(6):e09787. doi: 10.1016/j.heliyon.2022.e09787. PMID: 35800723; PMCID: PMC9253648. 2. Rudra DS, Pal U, Chowdhury N, Maiti NC, Bagchi A, Swarnakar S. Omeprazole prevents stress induced gastric ulcer by direct inhibition of MMP-2/TIMP-3 interactions. Free Radic Biol Med. 2022 Mar;181:221-234. doi: 10.1016/j.freeradbiomed.2022.02.007. Epub 2022 Feb 10. PMID: 35150824. |
1: Orbelo DM, Enders FT, Romero Y, Francis DL, Achem SR, Dabade TS, Crowell MD, Geno DM, DeJesus RS, Namasivayam V, Adamson SC, Arora AS, Majka AJ, Alexander JA, Murray JA, Lohse M, Diehl NN, Fredericksen M, Jung KW, Houston MS, O'Neil AE, Katzka DA. Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing. Dig Dis Sci. 2015 Jan;60(1):146-62. doi: 10.1007/s10620-013-3017-y. Epub 2014 Jan 22. PubMed PMID: 24448652.
2: Chiu CT, Hsu CM, Wang CC, Chang JJ, Sung CM, Lin CJ, Chen LW, Su MY, Chen TH. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013 Nov;38(9):1054-64. doi: 10.1111/apt.12482. Epub 2013 Sep 11. PubMed PMID: 24024757.
3: Qi Q, Wang R, Liu L, Zhao F, Wang S. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. Int J Clin Pharmacol Ther. 2015 Oct;53(10):803-10. doi: 10.5414/CP202396. Review. PubMed PMID: 26329348.
4: Nazir S, Iqbal Z, Ahmad L, Shah Y, Nasir F. Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle. Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):13-22. doi: 10.1007/s13318-013-0167-4. Epub 2014 Jan 5. PubMed PMID: 24390778.
5: Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, Nakata H, Katoh T, Miyamoto M, Tanaka S. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012 Jul;25(5):373-80. doi: 10.1111/j.1442-2050.2011.01276.x. Epub 2011 Nov 2. PubMed PMID: 22050449.
6: Birkmann K, Junge HK, Maischberger E, Wehrli Eser M, Schwarzwald CC. Efficacy of omeprazole powder paste or enteric-coated formulation in healing of gastric ulcers in horses. J Vet Intern Med. 2014 May-Jun;28(3):925-33. doi: 10.1111/jvim.12341. Epub 2014 Mar 14. PubMed PMID: 24628650; PubMed Central PMCID: PMC4895457.
7: Karim S, Baie SH, Hay YK, Bukhari NI. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion - spheronization process. Pak J Pharm Sci. 2014 May;27(3):425-38. PubMed PMID: 24811797.
8: Migoha CO, Ratansi M, Kaale E, Kagashe G. Preformulation studies for generic omeprazole magnesium enteric coated tablets. Biomed Res Int. 2015;2015:307032. doi: 10.1155/2015/307032. Epub 2015 Jan 28. PubMed PMID: 25699270; PubMed Central PMCID: PMC4324887.
9: Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 2013 Jul;41(7):1414-24. doi: 10.1124/dmd.113.051722. Epub 2013 Apr 25. PubMed PMID: 23620487; PubMed Central PMCID: PMC3684819.
10: Kuramoto T, Umegaki E, Nouda S, Narabayashi K, Kojima Y, Yoda Y, Ishida K, Kawakami K, Abe Y, Takeuchi T, Inoue T, Murano M, Tokioka S, Higuchi K. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol. 2013 May 14;13:85. doi: 10.1186/1471-230X-13-85. PubMed PMID: 23672202; PubMed Central PMCID: PMC3658908.
11: Whaley PA, Voudrie MA 2nd, Sorenson B. Stability of omeprazole in SyrSpend SF Alka (reconstituted). Int J Pharm Compd. 2012 Mar-Apr;16(2):164-6. PubMed PMID: 23050328.
12: Gerson LB, Mitra S, Bleker WF, Yeung P. Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy. Aliment Pharmacol Ther. 2012 Apr;35(7):803-9. doi: 10.1111/j.1365-2036.2012.05016.x. Epub 2012 Feb 22. PubMed PMID: 22356659.
13: Nevado JJ, Peñalvo GC, Dorado RM, Robledo VR. Simultaneous determination of omeprazole and their main metabolites in human urine samples by capillary electrophoresis using electrospray ionization-mass spectrometry detection. J Pharm Biomed Anal. 2014 Apr;92:211-9. doi: 10.1016/j.jpba.2013.12.020. Epub 2014 Jan 17. PubMed PMID: 24530982.
14: Iida H, Inamori M, Okuno K, Sekino Y, Sakai E, Okubo H, Higurashi T, Endo H, Hosono K, Yoneda M, Koide T, Takahashi H, Goto A, Kubota K, Saito S, Maeda S, Nakajima A, Gotoh E. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH. Hepatogastroenterology. 2015 Mar-Apr;62(138):493-6. PubMed PMID: 25916088.
15: Yamada S, Shiohira H, Yasui-Furukori N, Tateishi T, Akamine Y, Uno T. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers. Eur J Clin Pharmacol. 2013 Jul;69(7):1423-8. doi: 10.1007/s00228-013-1480-1. Epub 2013 Feb 24. PubMed PMID: 23435615.
16: Agatonovic-Kustrin S, Markovic N, Ginic-Markovic M, Mangan M, Glass BD. Compatibility studies between mannitol and omeprazole sodium isomers. J Pharm Biomed Anal. 2008 Sep 29;48(2):356-60. doi: 10.1016/j.jpba.2008.02.009. Epub 2008 Feb 17. PubMed PMID: 18374534.
17: Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol. 2012 Feb 23;12:18. doi: 10.1186/1471-230X-12-18. PubMed PMID: 22361121; PubMed Central PMCID: PMC3298711.
18: Karim S, Hay YK, Baie SH, Bukhari NI, Murtaza G. Study of comparative bioavailability of omeprazole pellets. Acta Pol Pharm. 2014 May-Jun;71(3):463-8. PubMed PMID: 25265826.
19: Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, Bucher M, Faerber L. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012 Aug;52(8):1265-72. doi: 10.1177/0091270011412968. Epub 2011 Sep 8. PubMed PMID: 21903891.
20: Karami S, Dehghanzadeh G, Haghighat M, Mirzaei R, Rahimi HR. Pharmacokinetic Comparison of Omeprazole Granule and Suspension Forms in Children: A Randomized, Parallel Pilot Trial. Drug Res (Stuttg). 2016 Mar;66(3):165-8. doi: 10.1055/s-0035-1564101. Epub 2015 Sep 23. PubMed PMID: 26398674.
